The meeting between SpectraCure and Memorial Sloan Kettering Cancer Center in New York, USA takes place tomorrow, March 13 2020

Refers to the latest travel information regarding the United States. The scheduled meeting, "Site Initiation Visit", between SpectraCure and Memorial Sloan Kettering Cancer Center in New York, USA, will be conducted tomorrow Friday. It is a formal meeting for the start-up and review of procedures and equipment. After the meeting is completed, the study is underway and recruitment of patients can begin.

For further information please contact:

Johannes Swartling, CTO SpectraCure. Telefon: +46 (0) 40-16 20 70, e-post: jsw@spectracure.com

Masoud Khayyami, CEO SpectraCure. E-post: mk@spectracure.com

Certified Adviser är G&W Fondkommission, e-post: ca@gwkapital.se, telefon: 08-503 000 50

www.spectracure.com

 

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region.

Tags:

About Us

SpectraCure's business concept is to, with its proprietary and patent-pending system, cure internal cancer tumors, prolong survival for cancer patients, and to act as complementary treatment options for other cancer treatments.

Subscribe

Documents & Links